Stock Track | Veracyte Plunges Over 7% After-Hours on Q4 2024 Earnings Miss

Stock Track

Feb 25, 2025

Shares of Veracyte (NASDAQ:VCYT) plummeted by 7.45% in after-hours trading on Monday, following the company's Q4 2024 earnings report that missed analyst estimates on profitability.

The molecular diagnostics company reported adjusted earnings per share of $0.06 for the quarter, falling short of the consensus estimate of $0.11 by a wide margin of 45.45%. While revenue for the period came in at $118.6 million, beating expectations of $116.765 million, the earnings miss overshadowed the top-line beat and weighed heavily on Veracyte's stock price.

Despite the quarterly earnings disappointment, Veracyte's Q4 2024 revenue grew by an impressive 20.78% year-over-year, driven by strong demand for its diagnostic tests. The company also provided guidance for its fiscal year 2025 testing revenue, projecting a range of $470 million to $480 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125040320"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125040320\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125040320?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125040320","market":"hk","top_or_hot":-1,"title":"Stock Track | Veracyte Plunges Over 7% After-Hours on Q4 2024 Earnings Miss","media":"Stock Track","content":"<p>Shares of Veracyte (NASDAQ:VCYT) plummeted by 7.45% in after-hours trading on Monday, following the company's Q4 2024 earnings report that missed analyst estimates on profitability.</p>\n\n<p>The molecular diagnostics company reported adjusted earnings per share of $0.06 for the quarter, falling short of the consensus estimate of $0.11 by a wide margin of 45.45%. While revenue for the period came in at $118.6 million, beating expectations of $116.765 million, the earnings miss overshadowed the top-line beat and weighed heavily on Veracyte's stock price.</p>\n\n<p>Despite the quarterly earnings disappointment, Veracyte's Q4 2024 revenue grew by an impressive 20.78% year-over-year, driven by strong demand for its diagnostic tests. The company also provided guidance for its fiscal year 2025 testing revenue, projecting a range of $470 million to $480 million.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Veracyte Plunges Over 7% After-Hours on Q4 2024 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Veracyte Plunges Over 7% After-Hours on Q4 2024 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 05:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Veracyte (NASDAQ:VCYT) plummeted by 7.45% in after-hours trading on Monday, following the company's Q4 2024 earnings report that missed analyst estimates on profitability.</p>\n\n<p>The molecular diagnostics company reported adjusted earnings per share of $0.06 for the quarter, falling short of the consensus estimate of $0.11 by a wide margin of 45.45%. While revenue for the period came in at $118.6 million, beating expectations of $116.765 million, the earnings miss overshadowed the top-line beat and weighed heavily on Veracyte's stock price.</p>\n\n<p>Despite the quarterly earnings disappointment, Veracyte's Q4 2024 revenue grew by an impressive 20.78% year-over-year, driven by strong demand for its diagnostic tests. The company also provided guidance for its fiscal year 2025 testing revenue, projecting a range of $470 million to $480 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"","article_id":"1125040320","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125040320","pubTimestamp":1740432890,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Veracyte  plummeted by 7.45% in after-hours trading on Monday, following the company's Q4 2024 earnings report that missed analyst estimates on profitability.The molecular diagnostics company reported adjusted earnings per share of $0.06 for the quarter, falling short of the consensus estimate of $0.11 by a wide margin of 45.45%. While revenue for the period came in at $118.6 million, beating expectations of $116.765 million, the earnings miss overshadowed the top-line beat and weighed","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc"},"translate_title":"股票跟踪Veracyte盘后暴跌超过7%，2024年第四季度盈利未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Shares of Veracyte (NASDAQ:VCYT) plummeted by 7.45% in after-hours trading on Monday, following the company's Q4 2024 earnings report that missed analyst estimates on profitability.\nThe molecular diagnostics company reported adjusted earnings per share of $0.06 for the quarter, falling short of the consensus estimate of $0.11 by a wide margin of 45.45%. While revenue for the period came in at $118.6 million, beating expectations of $116.765 million, the earnings miss overshadowed the top-line beat and weighed heavily on Veracyte's stock price.\nDespite the quarterly earnings disappointment, Veracyte's Q4 2024 revenue grew by an impressive 20.78% year-over-year, driven by strong demand for its diagnostic tests. The company also provided guidance for its fiscal year 2025 testing revenue, projecting a range of $470 million to $480 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}